The choice of the P2Y12 receptors blocker in the treatment of a patient with acute coronary syndrome: practice of N.I. Pirogov city clinical hospital №1

Ticagrelor is known to prefer clopidigrel except in cases of high risk of bleeding, but according to the literature, clopidogrel still remains the most frequent second component of dual antiplatelet therapy (DAPT) in the world. The aim of the study was to conduct comparative description of patient groups with the acid acetilsalicilic (ACS), taken depending on a prescription of clopidogrel or ticagrelor as the second component of DAPT according to data of the year’s work of the Pirogov City Clinical Hospital №1. Materials and methods: clinical data of 854 patients with ACS who undergone treatment in of Pirogov City Clinical Hospital №1 in 2017 were analyzed. Clopidogrel was prescribed to 623 patients (73%) – the I group, ticagrelor 231 (27%) – the II group. Patients in the I group compared to the II group were significantly older (70 and 62 years accordingly), women accounted for 43% in I group and 27% in II group. Arterial hypertension (96 and 89%), diabetes (34 and 26%), post-acute myocardial infarction (38 and 19%), chronic kidney disease (26 and 12%), anemia (15 and 7%). Among patients of II group final diagnosis of ST-elevation myocardial infarction (STEMI) was more often (64 and 31%), coronary angiography (CAG) and percutaneous coronary intervention (PCI) were more frequent – 98/94% and 88/75%, accordingly. Clopidogrel is prescribed to the patients more often in comparison with ticagrelor. Doctors make a choice in favor of clopidogrel for elderly patients, more often women and more comorbid patients. The presence of STEMI, as well as the performance of CAG / PCI in any definitive diagnosis, is associated with a relatively more frequent prescription of ticagrelor, and in elderly patients, the implementation of PCI is the only factor that significantly influences the choice of more active antiaggregant in DAPT.

acute coronary syndrome, antiplatelet therapy, clopidogrel, ticagrelor

1. Order of the Ministry of Health of the Russian Federation No. 405an «On approval of the specialized healthcare standard for unstable angina, acute and recurrent myocardial infarction (without ST segment elevation on the ECG)» of July 1, 2015.

2. Order of the Ministry of Health of the Russian Federation No. 404an «On approval of the specialized medical care standard for acute myocardial infarction (with ST segment elevation on the ECG)» of July 1, 2015]

3. Ibanez B., James St., Agewall St., Antunes M.J., Bucciarelli-Ducci Ch., Bueno H., Caforio A.L.P., Crea F., Goudevenos J.A., Halvorsen S., Hindricks G., Kastrati A., Lenzen M.J., Prescott E., Roffi M., Valgimigli M., Varenhorst Ch., Vranckx P., Widimský P., ESC Scientific Document Group; 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal. 2018 January 7;39(2):119–177. https://doi. org/10.1093/eurheartj/ehx393.

4. Roffi M., Patrono C., Collet J.-Ph., Mueller Ch., Valgimigli M., Andreotti F., Bax J.J., Borger M.A., Brotons C., Chew D.P., Gencer B., Hasenfuss G., Kjeldsen K., Lancellotti P., Landmesser U., Mehilli Ju., Mukherjee D., R.F. Storey, Windecker St., ESC Scientific Document Group; 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal. 2016 January14;37(3):267–315. https://doi. org/10.1093/eurheartj/ehv320.

5. Fitzgerald D.J., Maree A. Aspirin and clopidogrel resistance. Hematology. 2007:114-120. doi: 10.1182/asheducation-2007.1.114.

6. James St., Åkerblom A., Cannon Ch.P., Emanuelsson H., Husted St., Katus H., De Allan Skene, Steg Ph.G., Storey R.F., Harrington R., Becker R., Wallentin L. Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and b aseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J. 2009 Apr;157(4):599-605. https:// doi.org/10.1016/j.ahj.2009.01.003

7. Wallentin L., Becker R.C., Budaj A., Cannon C.P., Emanuelsson H., Held C., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–57. doi: 10.1056/NEJMoa0904327.

8. Olier I., Sirker A., Hildick-Smith D.J.R. on behalf of the British Cardiovascular Intervention Society and the National Institute for Cardiovascular Outcomes Research, et al Association of different antiplatelet therapies with mortality after primary percutaneous coronary intervention. Heart. 2018;104:1683-1690. http://dx.doi.org/10.1136/ heartjnl-2017-312366.

9. Motovska Z., Hlinomaz O., and Kala P. On behalf of the PRAGUE-18 Investigators Prasugrel Versus Ticagrelor in Patients With Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention: Multicenter Randomized PRAGUE-18 Study. Circulation. 2017;135(15):e887–e888. https:// doi.org/10.1161/CIRCULATIONAHA.117.027476.

10. Park K.-H., Jeong M.H., Ahn Y., Ahn T.H., Seung K.B., Oh D.J., et al. Comparison of short-term clinical outcomes between ticagrelor versus clopidogrel in patients with acute myocardial infarction undergoing successful revascularization; from Korea Acute Myocardial Infarction Registry-National Institute of Health. Int J Cardiol. 2016;215:193–200. doi: 10.1016/j. ijcard.2016.04.044.

11. Erlikh A.D., Gratsiansky N.A. and participants of the RECORD registry. Registry of Acute Coronary Syndromes «RECORD-3». Characteristics of Patients and Treatment During Initial Hospitalization. Kardiologiia. 2016;56(4):1624. (In Russ.)

12. Cannon Ch.P., Bhatt D.L., Oldgren J., Lip G.Y.H., Ellis St.G., Kimura T., Maeng M., Merkely B., Zeymer U., Gropper S., Nordaby M., Kleine E., et al., for the RE-DUAL PCI Steering Committee and Investigators Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med. 2017;377:1513-1524. doi: 10.1056/NEJMoa1708454.